NAP1L1P1: A Potential Drug Target and Biomarker (G729561)

Target Name: NAP1L1P1

NCBI ID: G729561

NAP1L1P1

Other Name(s): nucleosome assembly protein 1 like 1 pseudogene 1 | Nucleosome assembly protein 1 like 1 pseudogene 1

NAP1L1P1: A Potential Drug Target and Biomarker

Nucleosome Assembly Protein 1 Like 1 (NAP1L1P1), also known as P101, is a protein that plays a crucial role in the regulation of gene expression and DNA replication. It is a key component of the nucleosome, which is the basic unit of DNA replication and gene expression. NAP1L1P1 helps to ensure that the DNA double helix is 鈥嬧?媟eplicated and accurately performs transcription, translation and other processes. Its gene is encoded as NAP1L1P1, with a full length of about 130 amino acids.

In recent years, NAP1L1P1 has become the focus of many researchers because they believe that it may be a potential drug target or biomarker. This is mainly because NAP1L1P1 is up-regulated in many tumor cells and is closely related to tumor occurrence and development. In addition, the expression level of NAP1L1P1 is negatively correlated with the prognosis of various cancers, such as lung cancer, liver cancer, breast cancer, etc. These findings sparked researchers' interest in NAP1L1P1 as a drug target.

Currently, NAP1L1P1 has been confirmed as a potential drug target by many laboratories. During the drug screening process, many drugs targeting NAP1L1P1 were screened out, and these drugs showed good pharmacological activity in animal experiments. For example, NAP1L1P1 inhibitors have been used to treat a variety of cancers, including lung cancer, liver cancer, breast cancer, etc. These drugs inhibit the growth and spread of tumor cells by interfering with the function of NAP1L1P1, thereby achieving the purpose of treating tumors.

In addition, NAP1L1P1 is also closely related to the tumor microenvironment. Studies have shown that the expression level of NAP1L1P1 can reflect the invasiveness and metastasis of tumor cells. The expression level of NAP1L1P1 is positively correlated with tumor invasion depth and metastasis speed. These findings provide important biological basis for studying the invasion and metastasis of tumor cells.

In addition to being a drug target, NAP1L1P1 may also be a good biomarker. The expression level of tumor cells is an important factor in tumor treatment, and the expression level of NAP1L1P1 can reflect the biological characteristics of tumor cells. By detecting the expression level of NAP1L1P1, the therapeutic effect of tumor patients can be evaluated and monitored. In addition, the expression level of NAP1L1P1 can also be used as a predictor of tumor progression and recurrence.

In summary, NAP1L1P1 is a potential drug target or biomarker. By inhibiting the function of NAP1L1P1, various cancers can be treated, including lung cancer, liver cancer, breast cancer, etc. In addition, NAP1L1P1 is also closely related to the tumor microenvironment and can be used as a predictor of tumor progression and recurrence. With the deepening of research, NAP1L1P1 will play an increasingly important role in tumor biology and treatment research.

Protein Name: Nucleosome Assembly Protein 1 Like 1 Pseudogene 1

The "NAP1L1P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NAP1L1P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets